Jan Meijerink

Human cartilage glycoprotein‐39 as a candidate autoantigen in rheumatoid arthritis

Gijs Verheijden, Antonius W. M. Rijnders, Ebo Bos et al. · Arthritis & Rheumatism · 1997 · 210 citations · Full text

Life Sciences, Immunology, Molecular Biology +16

Localization of MHC Class II/Human Cartilage Glycoprotein-39 Complexes in Synovia of Rheumatoid Arthritis Patients Using Complex-Specific Monoclonal Antibodies

Peter G. A. Steenbakkers, Dominique Baeten, Eric Rovers et al. · The Journal of Immunology · 2003 · 63 citations · Full text

Life Sciences, Immunology, Molecular Biology +16

Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial.

Arthur Kavanaugh, Mark C. Genovese, Jan Baughman et al. · PubMed · 2003 · 29 citations

Life Sciences, Immunology, Pharmacology +17

Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial

Robert Landewé, J. G. A. Houbiers, Filip Van den Bosch et al. · Annals of the Rheumatic Diseases · 2009 · 16 citations

Life Sciences, Immunology, Pharmacology +17

Intranasal administration of recombinant human cartilage glycoprotein-39. A phase I escalating cohort study in patients with rheumatoid arthritis.

Michiel M Zandbelt, J. G. A. Houbiers, F.H.J. van den Hoogen et al. · PubMed · 2006 · 16 citations

Medicine, Internal Medicine, Pharmacotherapy +15